Last quarter (Q4 2023), Bolt Biotherapeutics's total revenue was $2.09M, an increase of 48.05% from the same quarter last year. In Q4, Bolt Biotherapeutics's net income was $-17.90M. See Bolt Biotherapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 7.88M	$ 7.88M	$ 5.73M	$ 1.26M	$ 231.00K	$ 215.00K
Cost of Revenue	-	-	-	-	-	-
Gross Profit	$ 7.88M	$ 7.88M	$ 5.73M	$ 1.26M	-	-
Operating Expense	$ 84.07M	$ 84.07M	$ 96.05M	$ 94.05M	$ 49.41M	$ 31.18M
Operating Income	$ -76.20M	$ -76.20M	$ -90.32M	$ -92.79M	$ -49.18M	$ -30.97M
Net Non Operating Interest Income Expense	$ 3.21M	-	-	$ -5.80M	$ 199.00K	$ 524.00K
Other Income Expense	$ -3.79M	$ -7.00M	$ -2.22M	-	$ -11.74M	$ -42.00K
Pretax Income	$ -69.20M	$ -69.20M	$ -88.10M	$ -98.59M	$ -60.73M	$ -30.49M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -69.20M	$ -69.20M	$ -88.10M	$ -98.59M	$ -60.73M	$ -30.49M
Basic EPS	$ -1.83	$ -1.83	$ -2.36	$ -2.97	$ -1.91	$ -3.23
Diluted EPS	$ -1.83	$ -1.83	$ -2.36	$ -2.97	$ -1.91	$ -3.23
Basic Average Shares	$ 151.25M	$ 37.81M	$ 37.36M	$ 33.20M	$ 31.85M	$ 9.42M
Diluted Average Shares	$ 151.25M	$ 37.81M	$ 37.36M	$ 33.20M	$ 31.85M	$ 9.42M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 84.07M	$ 84.07M	$ 96.05M	$ 94.05M	$ 49.41M	$ 31.18M
Net Income From Continuing And Discontinued Operation	$ -69.20M	$ -69.20M	$ -88.10M	$ -98.59M	$ -60.73M	$ -30.49M
Normalized Income	$ -41.25M	$ -54.67M	$ -69.60M	-	$ -48.98M	$ -30.45M
Interest Expense	-	-	-	-	-	-
EBIT	$ -70.63M	$ -69.20M	$ -88.10M	$ -92.79M	$ -49.18M	$ -30.97M
EBITDA	$ -53.93M	$ -68.88M	$ -83.02M	$ -86.46M	$ -48.57M	$ -30.63M

Currency in USD

Bolt Biotherapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing